# Dysport in Vulvodynia Phase II Study

> **NCT03598777** · PHASE2 · TERMINATED · sponsor: **Ipsen** · enrollment: 60 (actual)

## Conditions studied

- Vulvodynia

## Interventions

- **BIOLOGICAL:** Botulinum toxin type A
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03598777
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-11
- **Primary completion:** 2021-01-21
- **Final completion:** 2021-01-21
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** lack of efficacy
- **Last updated:** 2021-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03598777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03598777, "Dysport in Vulvodynia Phase II Study". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT03598777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*